ENTROPY NEURODYNAMICS LIMITED — Director's Dealing 2020

Dec 1, 2020

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Exopharm Limited
ABN	78 163 765 991

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

We (the entity) give ASX the followingthe director for the purposes of section	information under listing rule 3.19A.2 and as agent for205G of the Corporations Act.
Name of Director	Dr Ian E Dixon
Date of last notice	10 November 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest	Altnia Holdings Pty Ltd <Dixon Family A/C>
(including registered holder)	(Director and Controller)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change	2 December 2020
No. of securities held prior to change	27,975,294 Fully Paid Ordinary Shares
	250,000 Unlisted Performance Rights
Class	Fully Paid Ordinary Shares
Number acquired	200,000
Number disposed	Nil
Value/Consideration	Fully Paid Ordinary Shares issued for nil consideration
Note: If consideration is non-cash, provide details and estimatedvaluation	to Dr Ian Dixon as part of his Annual Bonus forsuccessful achievement of key performance indicators
	as set out in ASX Announcements dated 26 November
	2019, 29 October 2020 and 10 November 2020 and
	approved by shareholders at the Annual General
	Meeting held on 30 November 2020.

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change	28,175,294 Fully Paid Ordinary Shares
	250,000 Unlisted Performance Rights
Nature of change	Issue of Fully Paid Ordinary Shares to Dr Ian Dixon
Example: on-market trade, off-market trade, exercise of options,issue of securities under dividend reinvestment plan, participation inbuy-back	pursuant to his employment contract followingachievement of his key performance indicators, asapproved by Shareholders on 30 November 2020

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to which	N/A
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change	N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011